A North Carolina man is using the bad dream defense — telling a 911 operator he awoke from slumber to find his wife stabbed to death and drenched in blood, reports said. Matthew Phelps, 28, told the operator in Raleigh early Friday that he fell asleep after taking too much cold medicine and may have...
NYS Entity Status
NYS Filing Date
JANUARY 24, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION
2013 - NEW YORK PULMONARY & SLEEP MEDICINE, P.C.
Around the Web
- Husband thinks he killed wife in his sleep
By Gabrielle Fonrouge - Monday Sep 4, 2017
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
- New York Today: New York Today: New Subway Clocks
By JONATHAN WOLFE - Monday Aug 7, 2017
Monday: Rolling out new subway clocks, the Corkscrew Theater Festival, and National Lighthouse Day.
- Caught Sleeping or Worse, Troubled Teachers Will Return to New York Classrooms
By KATE TAYLOR - Friday Oct 13, 2017
To save money, schools will be forced to fill vacancies with educators who have lost their jobs but can’t be fired, despite fears some are incompetent or unstable.
- Restaurant Review: Lost in New York at Public Kitchen
By PETE WELLS - Tuesday Oct 10, 2017
At Jean-Georges Vongerichten’s new restaurant on the Lower East Side, the menu is supposed to be inspired by the whole city.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]